Vectura Group PLC (VEC.L)
81.85GBp
20 Feb 2019
-- (--)
81.85
--
--
--
--
973,722
107.80
65.85
About
Overall
| Beta: | 0.41 |
| Market Cap(Mil.): | £705.16 |
| Shares Outstanding(Mil.): | 679.34 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| VEC.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 30.48 | 33.70 |
| EPS (TTM): | -- | -- | -- |
| ROI: | -- | 14.95 | 14.45 |
| ROE: | -- | 16.27 | 15.96 |
Vectura hopes new respiratory device will breathe life into business
Vectura Group is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.
Vectura hopes new respiratory device will breathe life into business
Vectura Group is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.
UPDATE 3-Vectura hopes new respiratory device will breathe life into business
* Forecasts 2018 adjusted core earnings above market forecasts
UK drugmaker Vectura expects 2018 earnings to top market forecasts
Jan 3 British drugmaker Vectura Group Plc on Thursday predicted that its adjusted earnings in 2018 would top market expectations, helped in part by improving profit margins.
Vectura drops severe asthma treatment after poor trial results
Britain's Vectura Group Plc will stop developing its treatment for severe uncontrolled asthma after a trial showed it failed to have a significant impact on the condition.
Vectura drops severe asthma treatment after poor trial results
Britain's Vectura Group Plc will stop developing its treatment for severe uncontrolled asthma after a trial showed it failed to have a significant impact on the condition.
UPDATE 2-Vectura drops severe asthma treatment after poor trial results
* Shares fall more than 10 percent (Adds CEO, analyst comment, share movement)
Vectura to stop developing asthma treatment after late-stage failure
Nov 26 British drugmaker Vectura Group Plc said on Monday it would stop developing its treatment for severe uncontrolled asthma after the drug-device combination failed to meet the main goal of a late-stage study.
UPDATE 1-Vectura reviewing drug stockpiles as no-deal Brexit looms
Sept 11 British drugmaker Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its mitigation plan for a "no-deal" Brexit and warned on Tuesday of a potential disruption to supply chains and higher costs.
Vectura reviewing drug stockpiles as no-deal Brexit looms
Sept 11 Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its plan for a "no-deal" Brexit, the British drugmaker said on Tuesday, and warned of a potential disruption to supply chains and higher costs.
Earnings vs. 
Estimates
- Should You Ditch GlaxoSmithKline plc And Buy Vectura Group PLC And SkyePharma PLC?
- Are Vectura Group PLC, AstraZeneca plc And Lookers PLC 'Screaming Buys'?
- Are Vectura Group PLC And Circassia Pharmaceuticals PLC Better Buys Than GlaxoSmithKline plc?
- Why Vectura Group PLC Could Be The Perfect Partner For AstraZeneca plc In Your Portfolio
- Profit From The Biotech Boom With Vectura Group PLC, Hikma Pharmaceuticals Plc And Indivior PLC